文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

趋化因子CCL20及其受体CCR6在银屑病和银屑病关节炎发病机制及治疗中的作用

The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis.

作者信息

Shi Zhen-Rui, Mabuchi Tomotaka, Riutta Sarah J, Wu Xuesong, Peterson Francis C, Volkman Brian F, Hwang Sam T

机构信息

Department of Dermatology, Sun Yat-sen Memorial Hospital, Guang-zhou, China.

Department of Dermatology, Tokai University School of Medicine, Isehara, Japan.

出版信息

J Psoriasis Psoriatic Arthritis. 2023 Jul;8(3):107-117. doi: 10.1177/24755303231159106. Epub 2023 Mar 12.


DOI:10.1177/24755303231159106
PMID:39296310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11361516/
Abstract

BACKGROUND: Chemokines represent a superfamily of immune-modulatory small protein molecules that regulate leukocyte migration to inflammatory sites through their chemoattractant and cell signaling properties. This review focuses on the immunological functions of the CCR6 chemokine receptor and is chemokine ligand, CCL20, that contribute to it role in inflammation in human psoriasis. METHODS: Peer-reviewed relevant articles are searched and selected from 2000 to 2022 using the search engines including PubMed and Google Scholar. RESULTS: After selectively reviewing and evaluating over seventy articles, a comprehensive overview on the immunology of CCL20-CCR6 axis in psoriasis and psoriatic arthritis, the X-ray crystal structures of CCL20 monomers, and the potential of developing clinical therapies targeting this axis is summarized. CONCLUSIONS: Over the past decade, preclinical studies carried out in animal models of psoriasis involving agents targeting CCL20-CCR6 axis have yielded promising results. Other studies that this axis may play a role in a number of other autoimmune diseases, including rheumatoid arthritis, suggesting a rationale for further investigation into this key signaling/migratory pathway.

摘要

背景:趋化因子是一类免疫调节性小蛋白分子超家族,通过其趋化和细胞信号特性调节白细胞向炎症部位迁移。本综述聚焦于CCR6趋化因子受体及其趋化因子配体CCL20的免疫功能,它们在人类银屑病炎症中发挥作用。 方法:使用包括PubMed和谷歌学术在内的搜索引擎,检索并筛选2000年至2022年同行评议的相关文章。 结果:在对七十多篇文章进行选择性回顾和评估后,总结了银屑病和银屑病关节炎中CCL20-CCR6轴免疫学、CCL20单体的X射线晶体结构以及针对该轴开发临床疗法的潜力的全面概述。 结论:在过去十年中,在银屑病动物模型中开展的涉及靶向CCL20-CCR6轴药物的临床前研究取得了有前景的结果。其他研究表明,该轴可能在包括类风湿关节炎在内的许多其他自身免疫性疾病中起作用,这为进一步研究这一关键信号/迁移途径提供了理论依据。

相似文献

[1]
The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis.

J Psoriasis Psoriatic Arthritis. 2023-7

[2]
An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease.

Bioessays. 2010-10-15

[3]
Anti-psoriasis effect of 18β-glycyrrhetinic acid by breaking CCL20/CCR6 axis through its vital active group targeting GUSB/ATF2 signaling.

Phytomedicine. 2024-6

[4]
Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.

J Immunol. 2000-6-15

[5]
The CCL20-CCR6 Axis in Cancer Progression.

Int J Mol Sci. 2020-7-22

[6]
CCR6-CCL20 axis as a therapeutic target for autoimmune diseases.

Autoimmun Rev. 2021-7

[7]
Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model.

Proc Natl Acad Sci U S A. 2017-11-6

[8]
CCR6 as a possible therapeutic target in psoriasis.

Expert Opin Ther Targets. 2010-9

[9]
Expression of CC chemokine ligand 20 and CC chemokine receptor 6 mRNA in patients with psoriasis vulgaris.

J Huazhong Univ Sci Technolog Med Sci. 2004

[10]
Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation.

Arthritis Rheumatol. 2021-12

引用本文的文献

[1]
Systemic Psoriasis: From Molecular Mechanisms to Global Management Strategies.

Clin Rev Allergy Immunol. 2025-8-7

[2]
Psoriasis: Immunological and genetic blueprints driving pathogenesis and potential for personalized therapies.

Iran J Basic Med Sci. 2025

[3]
Association of +67 G/A and -426 T/C Polymorphism in Eotaxin (CCL11) Gene with Psoriasis Phenotypes.

Genes (Basel). 2025-2-27

本文引用的文献

[1]
Reduced CCR6IL-17ATreg Cells in Blood and CCR6-Dependent Accumulation of IL-17ATreg Cells in Lungs of Patients With Allergic Asthma.

Front Immunol. 2021-8-23

[2]
Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation.

Arthritis Rheumatol. 2021-12

[3]
Increased peripheral helper T cells type 17 subset correlates with the severity of psoriasis vulgaris.

Immunol Lett. 2021-1

[4]
The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3.

J Biol Chem. 2020-10-2

[5]
Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20.

Nat Commun. 2020-6-15

[6]
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.

BMJ. 2020-5-28

[7]
Differential Requirement for CCR6 in IL-23-Mediated Skin and Joint Inflammation.

J Invest Dermatol. 2020-12

[8]
Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+CD8+ T Cells in Psoriatic Arthritis.

Arthritis Rheumatol. 2020-2-4

[9]
Increased frequency of activated CD8 T cell effectors in patients with psoriatic arthritis.

Sci Rep. 2019-7-26

[10]
PD-1+CXCR5-CD4+T cells are correlated with the severity of systemic lupus erythematosus.

Rheumatology (Oxford). 2019-12-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索